Welcome to our dedicated page for Endo International plc news (Ticker: ENDP), a resource for investors and traders seeking the latest updates and insights on Endo International plc stock.
Endo International plc (OTC: ENDPQ) is a leading specialty pharmaceutical company dedicated to improving the lives of patients through innovative and high-quality therapies. With a global team of passionate professionals, Endo transforms insights into effective treatments and ensures these are available to those who need them most.
Endo's core business revolves around the development, manufacturing, and marketing of branded and generic pharmaceutical products. The company focuses on areas such as pain management, urology, endocrinology, and oncology, catering to various unmet medical needs. Over the years, Endo has built a robust portfolio of products that enhance the quality of life for patients worldwide.
Recent Achievements and Projects:
- On September 21, 2023, Endo announced the presentation of data from clinical studies of collagenase clostridium histolyticum (CCH) for treating plantar fibromatosis at the American Orthopaedic Foot & Ankle Society's annual meeting. These studies showed improvement in nodule hardness and patient satisfaction, with a consistent safety profile.
- Endo has completed a Phase 2 study of CCH and anticipates beginning the pivotal Phase 3 program later this year. This effort underscores Endo's commitment to developing nonsurgical treatment options for conditions like plantar fibromatosis.
Endo's financial condition is currently under strategic restructuring, including Chapter 11 proceedings, aimed at addressing the company's liabilities and ensuring long-term viability. Despite these challenges, Endo continues to prioritize its mission of delivering life-enhancing therapies.
Endo's partnerships and collaborations play a crucial role in its success. By working with healthcare professionals, research institutions, and other industry stakeholders, Endo stays at the forefront of pharmaceutical innovation and effectively meets market demands.
For more information about Endo and its latest news, visit www.endo.com or connect with the company on LinkedIn.
The Buxton Helmsley Group issued an open letter to shareholders of Endo International Plc, addressing serious issues regarding corporate malfeasance and inaccurate financial statements. BHG's letter follows private communications with the Company, highlighting concerns that may impact shareholder trust and investment stability. BHG urges a thorough review of Endo's financial practices and governance as stakeholders assess the implications for their investments in the company.
Endo International plc (NASDAQ: ENDP) reported Q1 2022 revenues of $652 million, down 9% from $718 million in Q1 2021. The company experienced a loss from continuing operations of $65 million, resulting in a diluted net loss per share of $0.28. While revenues from Sterile Injectables decreased by 22% due to generic competition, the Generic Pharmaceuticals segment saw a 3% increase, driven by the launch of the FDA-approved generic Chantix®. The company provided limited Q2 guidance amid market uncertainties, focusing on long-term product portfolio investments.
Endo International plc (NASDAQ: ENDP) has announced a new clinical study for Qwo® (collagenase clostridium histolyticum-aaes) aimed at treating moderate to severe cellulite in adult women. The study's design will be presented at the Symposium for Cosmetic Advances & Laser Education (SCALE) in Nashville, TN, from May 11-15, 2022. The multi-cohort study will explore interventions to reduce bruising associated with Qwo treatment, emphasizing Endo's commitment to ongoing research and development to enhance patient experiences. Results will be shared with healthcare providers for safety and efficacy evaluations.
Endo International plc (NASDAQ: ENDP) announced the acquisition of six injectable product candidates from Nevakar Injectables Inc. for $35 million. This acquisition significantly expands Endo's portfolio of ready-to-use injectables, aimed at improving patient care in critical settings. The first product launch is expected by 2025, with development, approval, and commercialization under Endo's control. The acquisition is anticipated to enhance operational efficiency in hospitals by reducing preparation errors and costs.
Endo International plc (NASDAQ: ENDP) announced that the Tennessee Court of Appeals has reversed a trial court's denial of a motion for recusal related to Clay County et al. v. Purdue Pharma, L.P. This ruling mandates a new judge for the ongoing case involving claims from 13 counties and 22 cities alleging Endo violated Tennessee's Drug Dealer Liability Act. Additionally, the court vacated sanctions imposed on Endo, including a default judgment for purported discovery violations, to uphold confidence in the judiciary.
Endo International plc (NASDAQ: ENDP) plans to announce its first-quarter 2022 financial results on May 5, 2022. A conference call and webcast will follow on May 6, 2022, at 7:30 am ET. The call can be accessed at a dial-in number for U.S./Canada and international callers. A replay option will be available until May 13, 2022. Endo is committed to delivering quality therapies, leveraging its global team to enhance lives.
Endo International announced the launch of premixed Ephedrine Sulfate Injection in 50 mg/10 ml single-use vials, enhancing operational efficiency for healthcare providers. This release marks the first product under an exclusive licensing agreement with Nevakar Injectables, focusing on five sterile injectables. The ready-to-use design aims to reduce waste, optimize workflow, and minimize preparation errors in hospitals, ultimately improving patient care.
Endo International (NASDAQ: ENDP) has launched its inaugural Living Our Values Award program to honor employees who exemplify the company's core values: Collaboration, Innovation, Integrity & Quality, Drive, and Empathy. Winners receive monetary awards, commemorative trophies, and recognition from the Senior Executive Leadership Team. Nominees are selected based on their contributions to the company's strategic priorities. This initiative emphasizes Endo's commitment to its mission of enhancing lives through quality therapies while celebrating employee excellence.
Endo International plc (NASDAQ: ENDP) has launched the Butt First campaign, featuring over 200 patient events to raise awareness about Qwo®, the first FDA-approved injectable treatment for cellulite in women. The campaign aims to empower women to discuss cellulite with their aesthetic providers and learn more about Qwo's benefits. With an emphasis on education and emotional connection, the campaign includes digital ads and partnerships in beauty and wellness. Notably, Qwo treats moderate to severe cellulite and has gained FDA approval since July 2020.
FAQ
What does Endo International plc do?
What recent achievements has Endo announced?
What are Endo's core therapeutic areas?
What is plantar fibromatosis?
What is Endo’s financial situation?
How is Endo addressing unmet medical needs?
Where can I find more information about Endo?
What is CCH and what is its significance?
Is CCH approved for treating plantar fibromatosis?
What partnerships does Endo engage in?
